Symbol | Exchange | Currency |
|---|
(Reuters) - Nektar Therapeutics (NASDAQ:NKTR) said on Monday it would lay off about 70% of its workforce, or more than 500 employees, after stopping the development of its key...
Pre-Open Stock Movers: Casa Systems , Inc. (Nasdaq: NASDAQ:CASA) 47% HIGHER; awarded a multi-year purchase contract from Verizon (NYSE:VZ) and Verizon will take a 9.9% stake.TG...
Shares of Nektar Therapeutics (NASDAQ:NKTR) are down over 33% in pre-open Monday after the company said it stopped all trials involving its key cancer drug after it had failed to...
Small-cap stocks are companies with a market capitalization between $300 million and $2 billion. Historically, such stocks have performed better than large-cap stocks, especially...
Nektar Therapeutics (NASDAQ:NKTR) is a $2B clinical trials biotech company, headquartered in San Francisco, CA. The stock has mostly been hovering around the $20 mark for most of...
For Immediate ReleaseChicago, IL – February 25, 2021 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts...
Nektar Therapeutics is a research-based biopharmaceutical company, which is focused on discovering and developing medicines in areas of unmet medical need. The Company's research and development pipeline of new investigational drugs includes potential therapies for oncology, immunology and virology. In oncology, it is studying several immuno-oncology (I-O) drug candidates, including bempegaldesleukin, NKTR-255 and NKTR-262. In immunology, it is focused on addressing imbalances in the immune system to restore the body's self-tolerance mechanisms and achieve immune homeostasis. In autoimmune disorders, its IL-2 T-regulatory cell stimulator NKTR-358 is being clinically studied in systemic lupus erythematosus, ulcerative colitis, psoriasis and atopic dermatitis. Its programs in virology area include studying bempegaldesleukin in treating individuals affected with COVID-19, and a preclinical research collaboration with Gilead Sciences Inc. (Gilead) to test the combination of NKTR-255.
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Sell | Strong Sell | Strong Sell | Strong Sell | Strong Sell |
| Technical Indicators | Strong Sell | Strong Sell | Buy | Strong Sell | Strong Sell |
| Summary | Strong Sell | Strong Sell | Neutral | Strong Sell | Strong Sell |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 81.89 | 83.47 | 81.01 | -3.42 | -4.01% | 4.88M | NYSE | |||
| 1.19 | 1.22 | 1.14 | +0.0400 | +3.48% | 5.45M | NYSE | |||
| 0.0006 | 0.0006 | 0.0006 | 0.00000 | 0.00% | 0.00 | OTC Markets | |||
| 11.12 | 11.52 | 10.84 | +0.47 | +4.41% | 23.40M | NYSE | |||
| 4.44 | 4.47 | 4.44 | 0.000 | 0.00% | 0.00 | NYSE | |||
| 8.31 | 8.32 | 8.07 | +0.15 | +1.84% | 5.16M | NYSE | |||
| 94.48 | 95.09 | 86.73 | +12.17 | +14.79% | 45.63M | NYSE | |||
| 39.58 | 39.93 | 39.29 | +0.18 | +0.46% | 6.47M | NYSE | |||
| 0.187 | 0.1931 | 0.187 | -0.0052 | -2.71% | 1.06M | NYSE | |||
| 38.94 | 39.27 | 38.71 | +0.45 | +1.17% | 3.98M | NYSE | |||
| 13.52 | 13.68 | 13.40 | +0.14 | +1.05% | 283.71K | NYSE | |||
| 46.13 | 47.10 | 45.24 | +0.96 | +2.13% | 314.77K | NYSE | |||
| 377.96 | 382.40 | 364.44 | +25.01 | +7.09% | 1.76M | NASDAQ | |||
| 0.662 | 0.689 | 0.64 | +0.017 | +2.64% | 508.25K | NASDAQ | |||
| 169.87 | 175.16 | 159.51 | +13.58 | +8.69% | 2.05M | NYSE |